Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
Wave Life Sciences (NASDAQ: WVE), a clinical-stage biotechnology company specializing in RNA medicines, has announced its upcoming Virtual Research Day scheduled for October 29, 2025, at 10:00 a.m. ET.
The company's management team will also participate in several investor conferences in September and October 2025, including the Bernstein Healthcare Forum, Stifel Virtual Cardiometabolic Forum, and Chardan's Genetic Medicines Conference. Live webcasts will be available through Wave's investor relations website, with replays accessible for a limited time after each event.
Wave Life Sciences (NASDAQ: WVE), azienda biotecnologica in fase clinica specializzata in farmaci RNA, ha annunciato la sua prossima Giornata di Ricerca Virtuale prevista per il 29 ottobre 2025 alle 10:00 ora orientale (ET).
Il team dirigenziale dell'azienda parteciperà anche a diverse conferenze per investitori a settembre e ottobre 2025, tra cui il Bernstein Healthcare Forum, il Stifel Virtual Cardiometabolic Forum e la Conferenza sui Medicinali Genetici di Chardan. Le dirette web saranno disponibili sul sito degli investitori di Wave, con repliche accessibili per un periodo limitato dopo ciascun evento.
Wave Life Sciences (NASDAQ: WVE), una empresa de biotecnología en fase clínica especializada en medicamentos de ARN, ha anunciado su próxima Día de Investigación Virtual programado para el 29 de octubre de 2025 a las 10:00 a. m. hora del Este (ET).
El equipo de dirección de la empresa también participará en varias conferencias para inversores en septiembre y octubre de 2025, incluyendo el Bernstein Healthcare Forum, el Stifel Virtual Cardiometabolic Forum y la Conferencia de Medicamentos Genéticos de Chardan. Las transmisiones en vivo estarán disponibles a través del sitio web de relaciones con inversores de Wave, con repeticiones disponibles por un tiempo limitado después de cada evento.
Wave Life Sciences (NASDAQ: WVE), RNA 의약품을 전문으로 하는 임상 단계의 생명공학 회사는 2025년 10월 29일 동부표준시 10:00에 예정된 가상 연구의 날을 발표했습니다.
회사의 경영진은 2025년 9월과 10월에 걸쳐 여러 차례의 투자자 회의에 참여할 예정이며, Bernstein Healthcare Forum, Stifel Virtual Cardiometabolic Forum, 및 Chardan의 유전 의약품 컨퍼런스가 포함됩니다. 라이브 웹캐스트는 Wave의 투자자 관계 웹사이트를 통해 제공되며, 각 행사가 끝난 후 일정 기간 동안 재방송이 가능합니다.
Wave Life Sciences (NASDAQ: WVE), entreprise biotechnologique en phase clinique spécialisée dans les médicaments à base d'ARN, a annoncé sa prochaine Journée de Recherche Virtuelle prévue le 29 octobre 2025 à 10 h, heure de l'Est (ET).
L'équipe de direction participera également à plusieurs conférences pour investisseurs en septembre et octobre 2025, notamment le Bernstein Healthcare Forum, le Stifel Virtual Cardiometabolic Forum et la Conférence sur les Médicaments Génétiques de Chardan. Des webdiffusions en direct seront disponibles sur le site des relations investisseurs de Wave, avec des rediffusions accessibles pendant une période limitée après chaque événement.
Wave Life Sciences (NASDAQ: WVE), ein klinisch fortgeschrittenes Biotechnologieunternehmen, das sich auf RNA-Medikamente spezialisiert hat, hat seinen bevorstehenden Virtuellen Forschungstag angekündigt, der am 29. Oktober 2025 um 10:00 Uhr Ostzeit stattfinden wird.
Das Management des Unternehmens wird auch an mehreren Investorenkonferenzen im September und Oktober 2025 teilnehmen, darunter das Bernstein Healthcare Forum, das Stifel Virtual Cardiometabolic Forum und die Chardan-Konferenz für genetische Medikamente. Live-Webcasts werden über die Investor-Relations-Website von Wave verfügbar sein, Wiederholungen stehen für einen begrenzten Zeitraum nach jeder Veranstaltung zur Verfügung.
Wave Life Sciences (NASDAQ: WVE)، شركة أحياء جزيئية في المرحلة السريرية تتخصص في أدوية RNA، أعلنت عن يوم البحث الافتراضي القادم المقرر في 29 أكتوبر 2025 الساعة 10:00 صباحاً بتوقيت شرق الولايات المتحدة.
سيشارك فريق إدارة الشركة أيضاً في عدة مؤتمرات للمستثمرين في سبتمبر وأكتوبر 2025، بما في ذلك منتدى بيرنستين للرعاية الصحية، منتدى ستايفل الافتراضي لعلم الأيض القلبي، ومؤتمر تشاردان للأدوية الوراثية. ستكون البثوث المباشرة متاحة عبر موقع علاقات المستثمرين الخاص بوڤي، ويمكن الوصول إلى الإعاداد لفترة محدودة بعد كل حدث.
Wave Life Sciences (NASDAQ: WVE)，一家专注于RNA药物的临床阶段生物技术公司，宣布其即将举行的虚拟研究日，定于2025年10月29日美国东部时间上午10:00。
公司管理层还将参加2025年9月和10月的多场投资者会议，包括Bernstein Healthcare Forum、Stifel Virtual Cardiometabolic Forum以及Chardan's Genetic Medicines Conference。现场网络直播将通过Wave的投资者关系网站提供，各场活动结束后限时重播。
- None.
- None.
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. In addition, members of Wave’s management team are scheduled to participate in several upcoming investor conferences. Details are as follows:
Bernstein 2nd Annual Healthcare Forum
Date: Wednesday, September 24, 2025 at 2:50 p.m. ET
Details: Erik Ingelsson, MD, PhD, Chief Scientific Officer, will participate in an analyst-led fireside chat
Stifel Virtual Cardiometabolic Forum
Date: Tuesday, September 30, 2025 at 1:00 p.m. ET
Details: Paul Bolno, MD, MBA, President and CEO, and Erik Ingelsson will participate in an analyst-led fireside chat
Chardan’s 9th Annual Genetic Medicines Conference
Date: Tuesday, October 21, 2025 at 1:00 p.m. ET
Details: Paul Bolno will participate in a panel discussing RNA editing therapeutics
Wave’s 2025 Virtual Research Day
Date: Wednesday, October 29, 2025 at 10:00 a.m. ET
Details: More details to follow
Live webcasts of these presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these presentations will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
FAQ
When is Wave Life Sciences (WVE) hosting its Virtual Research Day 2025?
Which investor conferences will Wave Life Sciences (WVE) attend in Fall 2025?
How can investors access Wave Life Sciences' (WVE) conference presentations?
Who will be representing Wave Life Sciences (WVE) at these conferences?
